Adiponectin has recently been shown to influence skeletal metabolism. Over-expression of adiponectin gene suppresses bone resorption and increases trabecular bone mass 1 . Bone marrow stromal cells from adiponectin-null mice had reduced mineralization capability 2 . Adiponectin, signalling via the adiponectin receptor 1 (AdipoR1) stimulates osteoblast differentiation 3 and inhibits osteoclastogenesis 4 . The globular form of adiponectin (gAd) signals via AdipoR1 and stimulates osteoblast differentiation 5 . Based on these observations, we hypothesized that gAd could restore bone loss in osteopenic rats.
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Recombinant gAd used in this study has the following features 6 : q 18kD c-terminal globular domain, cloned from human genomic DNA.
q The protein activity is tested in C2C12 cell line for phosphorylation of AMPK and in MCF7 cell line for induction of ACC phosphorylation (Ser79).
q Expressed in E.coli as bacterial inclusion bodies and solubilized by alkaline shock.
Results: In vitro
Effect on osteoblast: 
Effect on osteoclast:
Figure 3: gAd inhibited osteoclast formation (TRAP staining) and decreased osteoclast marker expression in bone marrow-derived osteoclast progenitor cells. The skeletal effect of recombinant globular adiponectin (gAd) was tested in preclinical model of post-menopausal osteoporosis (ovariectomized rats). gAd restored trabecular bone microarchitecture in osteopenic rats up to the level of control. gAd accelerates fracture healing and improves bone micro-architecture in postmenopausal osteoporosis model likely via osteogenic and anti-resorptive modes. So, gAd can be a potential therapeutic candidate for postmenopausal osteoporosis. 
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